As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

John Carroll

The cascade of venture cash into -Cas9 startups is continuing with no end in sight, despite a brawl brewing over who owns the technology. Today it's ' turn at the venture well, drawing $ 64 million in new VC cash that will fund a company that's based in Basel with deep and growing roots in Cambridge, MA. The new funding brings its total haul to $ 89 million, with GlaxoSmithKline's SR One and leading the way.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS